News
Public · Published
Cathie Wood Loads Up On TEM, ILMN And Biotech Stocks — But Pares Stake In This Pharma Giant That Had A Blowout Q3
ARK Invest's actively managed funds made several stock trades on Friday, buying shares in Tempus AI, Illumina and other biotechnology companies while reducing some established holdings. The supplied article identifies Eli Lilly as a surprising sale, but its text cuts off before giving the number of shares or further details.
Published:
Updated:
What happened
ARK Invest’s actively managed funds made several stock trades on Friday, buying shares in Tempus AI, Illumina and other biotechnology companies while reducing some established holdings. The supplied article identifies Eli Lilly as a surprising sale, but its text cuts off before giving the number of shares or further details.
Confirmed
Global impact / market context
The purchases increase the funds’ exposure to companies working in healthcare, genomics and biotechnology, while the reported Lilly sale points in the opposite direction. If these holdings rise or fall, their performance can affect the funds’ returns; the article gives no reason for the trades.
Analyst inference
The article describes trades across several actively managed ETFs, including funds focused on genomics and innovation. It reports share counts for some purchases but does not provide trade values, fund weights, or the amount of Lilly shares sold, limiting conclusions about the size of the shift.
Confirmed
What to watch
- Further details on the Lilly sale would clarify how many shares ARK reduced and whether the move was a small adjustment or a larger portfolio change. Analyst inference
- Subsequent fund disclosures could show whether ARK continues buying Tempus AI, Illumina and other biotechnology stocks or reverses these additions. Analyst inference
- The article does not explain why ARK traded these stocks, so any claim that the moves reflect a changed view of their business prospects remains unconfirmed. Confirmed